loader image
Friday, December 12, 2025
67.9 F
McAllen
- Advertisement -

Research Reveals Genetic Link to Most Common Pediatric Bone Cancer

Translate to Spanish or other 102 languages!

Researchers at Cleveland Clinic Children’s have helped identify a gene that increases the risk of developing osteosarcoma, which is the most common type of bone cancer in children and young adults. Image for illustration purposes
Researchers at Cleveland Clinic Children’s have helped identify a gene that increases the risk of developing osteosarcoma, which is the most common type of bone cancer in children and young adults. Image for illustration purposes
- Advertisement -

CLEVELAND CLINIC – Researchers at Cleveland Clinic Children’s have helped identify a gene that increases the risk of developing osteosarcoma, which is the most common type of bone cancer in children and young adults. 

“Osteosarcoma is a very malignant, aggressive cancer that has a poor prognosis. And thus far, it doesn’t have a lot of genes that we can test for that would tell you that you’re at risk for this cancer. Well, SMARCAL1 one happens to be one of those genes that we can now actually test for in families that have history of cancers, or history of this particular osteosarcoma cancer,” said Richa Sharma, MD, hematologist and oncologist at Cleveland Clinic Children’s.

Dr. Sharma, who led the research, said they analyzed genetic information from nearly 6,000 children with cancer and compared it to more than 14,000 adults with cancer. 

- Advertisement -

Ultimately, they found one gene in particular had a significant risk factor for osteosarcoma. 

In addition, approximately 2.6% of children with osteosarcoma had inherited mutations of that gene, which Dr. Sharma said may weaken DNA repair and promote tumor growth. 

She explained that these findings could be helpful not only for future risk assessment but also for potential therapies. 

“From a therapy perspective, this is where scientists really need to collaborate and get together and understand how SMARCAL1 drives tumor biology, because that is how you’re going to achieve targetable therapies. And so, it has bigger potential, but the science is behind. We need to catch up now and try to connect the dots,” said Dr. Sharma. 

- Advertisement -

Reports show that fewer than 1,000 people in the United States develop osteosarcoma each year. 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Children’s Receives Visit From Trooper Santa

For the second year in a row, the Texas DPS Troopers Foundation helped spread holiday cheer to hospitalized patients at STHS Children’s during meet & greet with Trooper Santa.

FDA Approves Zenflow Spring® System for BPH Treatment

 Zenflow, Inc. announced today the U.S. Food and Drug Administration (FDA) approval of the Zenflow Spring® Implant and Delivery System for the treatment of symptoms associated with benign prostatic hyperplasia (BPH), also known as enlarged prostate.

Paxton Sues Medical Records Giant for Blocking Data and Parental Access

Attorney General Ken Paxton filed a lawsuit against Epic Systems Corporation (“Epic”) for their unlawful monopolization of the electronic health records industry and for engaging in deceptive practices that restrict parental access to their minor children’s medical records.

CDC’s Rapid Response Helps Solve First Infant Botulism Outbreak Linked to Formula

The Centers for Disease Control and Prevention (CDC) released an update on the ongoing investigation of infant botulism cases linked to ByHeart infant formula.
- Advertisement -
×